Pegaspargase

Pegaspargase
Names
Pronunciation/pəˈɡæspərɡeɪz/
Trade namesOncaspar
IUPAC name
  • Pegylated E. coli L-asparagine amidohydrolase
Clinical data
Main usesAcute lymphoblastic leukemia (ALL)[1]
Side effectsAllergic reactions, blood clotting problems, high blood sugar, liver problems, pancreas inflammation, blood clots in the brain[2]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    use    		Intramuscular injection (IM), intravenous (IV)
    Defined daily doseNot established[3]
    External links
    AHFS/Drugs.comMonograph
    MedlinePlusa695031
    Legal
    License data
    Legal status
    Chemical and physical data
    FormulaC1377H2208N382O442S17
    Molar mass31732.06 g·mol−1

    Pegaspargase, sold under the trade name Oncaspar, is a medication used in the treatment of acute lymphoblastic leukemia (ALL).[1] Often it is used together with anthracycline, vincristine, and prednisone.[2] It is used by injection.[2]

    Common side effects include allergic reactions, blood clotting problems, high blood sugar, liver problems, pancreas inflammation, and blood clots in the brain.[2] Its use during pregnancy may harm the baby.[4] It is a modified version of the enzyme asparaginase which has undergone PEGylation.[5][2] It works by breaking down asparagine, decreasing its availability to make protein.[2]

    Pegaspargase was approved for medical use in the United States in 1994.[2] It is on the World Health Organization's List of Essential Medicines.[6] It is made by Sigma-Tau.[2] In the United States it costs about $US17,800 per 3,750 units vial.[7]

    Dosage

    The defined daily dose is not established.[3]

    References

    1. 1 2 Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.
    2. 1 2 3 4 5 6 7 8 "Pegaspargase Monograph for Professionals". Drugs.com. Archived from the original on 17 August 2019. Retrieved 11 October 2019.
    3. 1 2 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 25 November 2020. Retrieved 9 September 2020.
    4. ↑ "Pegaspargase (Oncaspar) Use During Pregnancy". Drugs.com. Archived from the original on 11 October 2019. Retrieved 11 October 2019.
    5. ↑ "UNM Cancer Center". Archived from the original on 3 September 2006. Retrieved 28 August 2007.
    6. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
    7. ↑ "Oncaspar Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 13 May 2020. Retrieved 11 October 2019.
    External sites:
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.